Molecular Formula: C₂₂₃H₃₇₀N₇₂O₆₉S
Molecular Weight: 5195.908 g/mol
Sequence: GHRH(1-44) with trans-3-hexenoic acid modification
Purity: >99% Vial Size: 5mg Storage: -20°C, protect from light
Product Overview
Tesamorelin represents advanced growth hormone-releasing hormone (GHRH) analog technology designed for comprehensive metabolic, cardiovascular, and neurological research applications. This FDA-approved synthetic 44-amino acid peptide features enhanced stability through trans-3-hexenoic acid modification, providing 4x greater potency than native GHRH while maintaining physiological pulsatile growth hormone release patterns. Unlike direct growth hormone administration, Tesamorelin preserves natural feedback mechanisms through the hypothalamic-pituitary axis.
Revolutionary GHRH Mechanism
Tesamorelin functions as a highly selective GHRH receptor agonist in the anterior pituitary, stimulating endogenous growth hormone synthesis and release while subsequently increasing IGF-1 and IGFBP-3 levels. The peptide's unique trans-3-hexenoic acid modification provides enhanced plasma stability and extended half-life compared to native GHRH, enabling sustained receptor activation for detailed mechanistic investigations across multiple physiological systems.
Primary Research Applications
HIV-Associated Lipodystrophy Research
FDA-approved clinical validation demonstrates 15-20% reduction in visceral adipose tissue without affecting subcutaneous fat. Studies show significant improvements in body composition, waist circumference reduction, and enhanced patient self-image scores. Research applications include investigating antiretroviral therapy complications and metabolic dysfunction mechanisms.
Cardiovascular Protection Studies
Clinical trials reveal significant improvements in triglyceride levels, total cholesterol, and non-HDL cholesterol. Research demonstrates 50mg triglyceride reduction correlating with 15% visceral fat decrease. Applications include investigating cardiovascular disease prevention in HIV populations and metabolic syndrome interventions.
Cognitive Enhancement Research
Emerging studies demonstrate neuroprotective effects through GABA level increases and myo-inositol reduction in brain tissue. Research shows improvements in executive function and verbal memory in mild cognitive impairment models. Applications include dementia prevention studies and age-related cognitive decline research.
Skeletal Muscle Research
Clinical data shows significant increases in muscle density (1.56-4.86 Hounsfield units) and lean muscle area (0.64-1.08 cm²) across trunk muscle groups. Research applications include sarcopenia studies, age-related muscle loss investigations, and exercise enhancement mechanisms.
Peripheral Nerve Studies
Research demonstrates enhanced nerve regeneration rates and improved healing outcomes following injury. Applications include diabetic neuropathy research, surgical recovery studies, and neuroplasticity investigations through growth hormone pathway activation.
Mechanism of Action
Growth Hormone Stimulation: Pulsatile GH release maintaining physiological patterns IGF-1 Activation: Sustained increases in growth factor signaling Lipolytic Effects: Selective visceral adipose tissue reduction Anabolic Actions: Enhanced protein synthesis and muscle development Neuroprotection: GABA modulation and cognitive enhancement Cardiovascular Benefits: Lipid profile improvements and metabolic optimization
Research Advantages
Enhanced Stability: 4x more potent than native GHRH
Physiological Action: Preserves natural pulsatile GH release
Multi-System Effects: Metabolic, cardiovascular, neural applications
Clinical Validation: FDA-approved with extensive Phase III data
Selective Targeting: Visceral fat reduction without subcutaneous effects
Cognitive Benefits: Demonstrated improvements in memory and function
Safety Profile: Well-tolerated with minimal adverse effects
Quality Specifications
Every Tesamorelin batch undergoes comprehensive quality control:
HPLC-MS purity analysis confirming >99% purity
Amino acid sequence verification and molecular weight confirmation
Trans-3-hexenoic acid modification validation
Endotoxin testing (<0.1 EU/mg)
Stability testing and degradation analysis
Bioactivity assays using GHRH receptor cell lines
Certificate of Analysis provided with each shipment
Storage & Reconstitution
Store lyophilized powder at -20°C in sealed vials. Protect from light and humidity. Reconstitute with bacteriostatic water immediately before use. Once reconstituted, use within 24 hours or store at -80°C for short-term applications. Avoid repeated freeze-thaw cycles to maintain receptor binding affinity and biological activity.
Research Protocol Applications
HIV-associated lipodystrophy mechanism studies
Growth hormone axis regulation research
Cardiovascular disease prevention investigations
Cognitive enhancement and neuroprotection studies
Skeletal muscle development and sarcopenia research
Peripheral nerve regeneration studies
Metabolic syndrome and diabetes complications research
Anti-aging and longevity mechanism investigations
Clinical Translation Potential
Tesamorelin research benefits from extensive clinical validation through multiple Phase III trials involving over 800 HIV-infected patients. The peptide's proven efficacy in reducing visceral adiposity, improving cardiovascular markers, and enhancing cognitive function provides robust foundation for investigating novel therapeutic applications in metabolic disorders, neurodegenerative diseases, and age-related conditions.
Research Use Only: Not for human or veterinary therapeutic applications. Handle according to laboratory safety protocols and institutional research guidelines.